Logo do repositório
 
Publicação

Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs

2021-01Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRuponen, Marika
dc.contributor.authorKettunen, Konsta
dc.contributor.authorPires, Monica Santiago
dc.contributor.authorLaitinen, Riikka
dc.date.accessioned2021-02-12T16:58:58Z
dc.date.available2021-02-12T16:58:58Z
dc.date.issued2021-01
dc.description.abstractIn this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRuponen M, Kettunen K, Pires MS, Laitinen R. Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs. Pharmaceutics. 2021;13(2):171.pt_PT
dc.identifier.doi10.3390/pharmaceutics13020171pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/12836
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/2/171pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectCo-amorphouspt_PT
dc.subjectDissolutionpt_PT
dc.subjectStabilitypt_PT
dc.subjectSolubilitypt_PT
dc.subjectPermeationpt_PT
dc.subjectP-gp inhibitorpt_PT
dc.titleCo-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue2pt_PT
oaire.citation.startPage171pt_PT
oaire.citation.titlePharmaceuticspt_PT
oaire.citation.volume13pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs.pdf
Tamanho:
3.11 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

ESTeSL - Artigos